Experimental treatment with Favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof of concept trial in Guinea, PLoS Med, vol.13, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01327168
Favipiravir pharmacokinetics in Ebola-infected patients of the JIKI trial reveals concentrations lower than targeted, PLoS Negl Trop Dis, vol.11, issue.2, p.5389, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02309055
QTc interval prolongation during favipiravir therapy in an Ebola virus-infected patient, PLoS Negl Trop Dis, vol.11, issue.12, 2017. ,
, Guidance for industry. E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), 2005.
Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG, Mol Pharmacol, vol.59, pp.122-126, 2001. ,
, Crediblemeds.org, QTdrugs List, Accession Date
Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG, J Pharmacol Exp Ther, vol.299, pp.290-296, 2001. ,
Coupling data mining and laboratory experiments to discover drug interactions causing QT prolongation, J Am Coll Cardiol, vol.68, pp.1756-1764, 2016. ,
Lack of effect of favipiravir, a novel antiviral agent, on the QT interval in healthy Japanese adults, Int J Clin Pharmacol Ther, vol.53, pp.866-874, 2015. ,
Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in adults-NCT02026349 ClinicalTrials ,
Laboratory findings, compassionate use of favipiravir, and outcome in patients with Ebola virus disease, Guinea, 2015-A retrospective observational study, J Infect Dis, vol.220, issue.2, pp.195-202, 2019. ,
, PREVAIL II Writing Group
A randomized, controlled trial of ZMapp for Ebola virus infection, N Engl J Med, vol.375, issue.15, pp.1448-1456, 2016. ,
Resurgence of Ebola virus disease in Guinea linked to a survivor with virus persistence in seminal fluid for more than 500 days, Clin Infect Dis, vol.63, issue.10, pp.1353-1356, 2016. ,
A randomized, controlled trial of Ebola virus disease therapeutics, 2019. ,
, N Engl J Med, 2019.